AbbVie Inc. $ABBV is Vaughan David Investments LLC IL’s 9th Largest Position

Posted by Francis Steltz on Jun 12th, 2026

Vaughan David Investments LLC IL lessened its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 332,800 shares of the company’s stock after selling 3,664 shares during the period. AbbVie makes up approximately 1.6% of Vaughan David Investments LLC IL’s portfolio, making the stock its 9th largest position. Vaughan David Investments LLC IL’s holdings in AbbVie were worth $76,041,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Norges Bank purchased a new position in AbbVie in the 4th quarter valued at approximately $5,865,055,000. Wellington Management Group LLP boosted its position in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Capital World Investors boosted its position in AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after buying an additional 6,736,161 shares during the period. Geode Capital Management LLC boosted its position in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares during the period. Finally, Vanguard Group Inc. boosted its position in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after buying an additional 3,032,438 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie said new Phase 3 data for venetoclax in first-line chronic lymphocytic leukemia showed durable, long-term treatment outcomes, supporting confidence in the drug’s commercial runway and oncology pipeline. Article link
Positive Sentiment: AbbVie’s Skyrizi and Rinvoq continue to drive top-line growth, with strong first-quarter performance and new indications helping lift 2026 sales expectations. Article link
Positive Sentiment: One article highlighted that promising clinical updates could help AbbVie fund future dividend growth, reinforcing the stock’s appeal for income-focused investors. Article link
Neutral Sentiment: AbbVie was also mentioned in market commentary and “final trades” segments, which can increase attention but do not by themselves change the company’s fundamentals. Article link
Negative Sentiment: AbbVie received a Complete Response Letter for its fast-acting neurotoxin TrenibotE, with the FDA citing manufacturing issues; while no safety or efficacy concerns were raised, the setback delays a potentially important aesthetics product. Article link

AbbVie Price Performance

Shares of NYSE:ABBV opened at $225.04 on Friday. The company’s fifty day moving average price is $210.80 and its 200 day moving average price is $219.01. AbbVie Inc. has a 12 month low of $181.73 and a 12 month high of $244.81. The firm has a market capitalization of $397.60 billion, a P/E ratio of 110.86, a P/E/G ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the business earned $2.46 EPS. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Morgan Stanley lifted their price objective on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Monday. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Piper Sandler lifted their price objective on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

View Our Latest Research Report on AbbVie

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.